Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
A phase 1/2 trial of ADC in prostate cancer, colorectal cancer and pancreatic ductal adenocarcinoma, run by MBrace Therapeutics, now recruiting.
Overview
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors is a phase 1/2 interventional study registered as NCT07145255 by MBrace Therapeutics, with 150 participants planned, started 2025-09-03 and due to reach its primary completion in 2029-09-30. Interventions recorded: ADC.
Similar pages
not linked directly; found by shared links- TrialSafety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
Shares MBrace Therapeutics and the tag pipeline.
- TrialA Study of DM002 in Patients With Advanced Solid Tumors
Shares Pancreatic ductal adenocarcinoma, Prostate cancer, Colorectal cancer and the tag pipeline.
- TrialPhase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
- TrialA Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Shares Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
- TrialPhase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
Shares Pancreatic ductal adenocarcinoma, Prostate cancer, Colorectal cancer and the tag pipeline.
- TrialA Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
- TrialPsilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
Shares Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
- TrialA Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.